Clinical Trial Update: Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Luveltamab Tazevibulin (STRO-002) for relapsed/refractory CBFA2T3::GLIS2 AML in infants and children under 12 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Luveltamab Tazevibulin (STRO-002) (Luveltamab Tazevibulin)

Snippet

Sponsor: Sutro Biopharma, Inc. | Conditions: Acute Myeloid Leukemia (AML) | Phase 1, Phase 2 | Status: TERMINATED